Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00280423 · ClinicalTrials.gov registry record · Phase 2
Effects Of GW679769 On Sleep Onset And Maintenance And Next Day Functioning In Subjects With Primary Insomnia
A Phase 2 study of Insomnia and Sleep Initiation and Maintenance Disorders, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 342
- Enrollment target
- 20
- Study locations
NCT00280423: Completed Phase 2 study of Insomnia and Sleep Initiation and Maintenance Disorders, sponsored by GlaxoSmithKline.
NCT00280423 is a Phase 2 study of Insomnia and Sleep Initiation and Maintenance Disorders that has completed, run by GlaxoSmithKline. The registered enrollment target is 342 participants, above the 168-participant average among 151 other Insomnia trials with a reported enrollment target (104% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00280423, a Phase 2 study of Insomnia and Sleep Initiation and Maintenance Disorders, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 342 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is designed to find the optimal (best) doses of GW679769 that could be given daily to promote sleep onset and maintain sleep during the night without significant next-day thinking impairment and drowsiness in subjects with primary insomnia.
Conditions Studied
Interventions
- DRUG GW679769
Study Locations (20)
California
- GSK Investigational Site - Burbank
- GSK Investigational Site - Huntington Beach
- GSK Investigational Site - Irvine
- GSK Investigational Site - Los Angeles
- GSK Investigational Site - National City
- GSK Investigational Site - San Diego
- GSK Investigational Site - San Diego
- GSK Investigational Site - San Diego
- GSK Investigational Site - San Francisco
- GSK Investigational Site - Santa Rosa
Florida
- GSK Investigational Site - DeLand
- GSK Investigational Site - Delray Beach
- GSK Investigational Site - Hallandale
- GSK Investigational Site - Largo
- GSK Investigational Site - Miami
Arizona
- GSK Investigational Site - Phoenix
- GSK Investigational Site - Tucson
Alabama
- GSK Investigational Site - Birmingham
Arkansas
- GSK Investigational Site - Little Rock
Connecticut
- GSK Investigational Site - Norwalk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 342 participants |
| Start Date | 2006-01 |
| Est. Completion | 2007-02 |
| Phase | Phase 2 |
What the finished NCT00280423 record still lists
NCT00280423 is an interventional study that assigns participants to a tested intervention. The registered 342 participants enrollment target is mid-sized for trials with a published cap, above the 168-participant average among 151 other Insomnia trials with a reported enrollment target (104% higher).
The record links to 2 conditions, with Insomnia appearing as the primary indexed condition, and to 1 intervention - of which GW679769 is the first listed.
NCT00280423 names 20 study sites across 6 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT00280423 about?
NCT00280423 is a clinical study titled "Effects Of GW679769 On Sleep Onset And Maintenance And Next Day Functioning In Subjects With Primary Insomnia". This study is designed to find the optimal (best) doses of GW679769 that could be given daily to promote sleep onset and maintain sleep during the night without significant next-day thinking impairment and drowsiness in subjects with primary insomnia.
What is the current status of trial NCT00280423?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 342 participants. The study started on 2006-01. Estimated completion is 2007-02.
What conditions does trial NCT00280423 study?
This clinical trial studies the following conditions: Insomnia, Sleep Initiation and Maintenance Disorders.
What interventions are being tested in trial NCT00280423?
The interventions under investigation include: GW679769 (DRUG).
Who is sponsoring clinical trial NCT00280423?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00280423 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Insomnia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00280423's enrollment target sits among peer trials
342 19th of 151 higher than 133 of 151 other Insomnia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Insomnia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sleep to Reduce Incident Depression Effectively in Peripartum
RECRUITING · Phase 2
-
Pimavanserin for Insomnia in Veterans With PTSD
RECRUITING · Phase 2
-
Neural Mechanisms Connecting Deficient Sleep and Smoking Relapse
RECRUITING · Phase 2
-
Sleep Healthy Using the Internet Mitigating Insomnia to Address Neurocognitive Difficulties (SHUTi MIND)
RECRUITING · Phase 2
-
Suvorexant for Treatment of AUD and PTSD
RECRUITING · Phase 2
-
Efficacy of Cognitive Behavioral Therapy for Insomnia to Treat Insomnia Symptoms in Individuals With Multiple Sclerosis
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05283850 · 342 participants · Phase 2
Surviving PEA in Roanoke (SPEAR) Study
- NCT05714085 · 342 participants · Phase 2
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
- NCT06188702 · 342 participants · Phase 1
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
- NCT06544941 · 342 participants · NA
Improving Maternal Sleep and Mental Health
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia